Drug intelligence / Profile preview

GWZ004

Development stage: Preclinical
Lead developer: Ginwa Enterprise Group
Administration: Topical

Overview

GWZ004 is a traditional Chinese medicine (TCM) candidate being developed as a topical preparation for the treatment of knee osteoarthritis. It is classified as a TCM Class 1.1 new drug by the developer, GINWA Pharmaceutical Factory. Currently in the preclinical stage, specifically undergoing druggability research, the drug is designed for localized application to manage symptoms associated with osteoarthritis of the knee. As a Class 1.1 TCM, it represents an innovative formulation or a new therapeutic use of traditional ingredients that has not previously been marketed in China.

Beyond the preview

Go deeper on GWZ004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GWZ004.

Explore the full profile